The Jenex Corporation
  the Jenex Corporation Stock Quote: JEN  
  Investor Information Circular  
  Testimonials  
  Frequently Asked Questions  
  Public Filings  
  If you would like to receive press releases and other company information, enter email address below.  
 
subscribe
unsubscribe
 
Market Opportunity
 
The Jenex Corporation Announces


  THE JENEX CORPORATION

Burlington, Ontario – The Jenex Corporation (TSX Venture – “JEN”) (the “Corporation”).  Mr. Michael Jenkins, President and CEO of The Jenex Corporation is pleased to announce the addition of Mr. Wayne Izumi to their Board of Directors.  Mr. Izumi is a successful businessman, entrepreneur and a well respected member of the community.  Mr. Izumi is President of Stoller Canada Inc., a Canadian agricultural chemical company and Izumi Outdoors Inc., a multi-media company.

 

Mr. Michael Rowell has tendered his resignation from the Board of Directors of the Corporation effective May 29, 2003.  The Board of Directors thanks Mr. Rowell for his dedicated service and wish him well with future endeavors.

 

About The Jenex Corporation

Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. The Corporation is preparing to launch their cold sore prevention device in the Canadian market in early 2004. Jenex has clearance to market the cold sore device in Canada with their approved claim “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. Regulatory approvals will be pursued for USA, Europe and Australia.  The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.

 

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

 

For further information contact:

 

The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario
L7L 5K6

Attention: Michael A. Jenkins, President
Telephone: (905) 632-3830  Facsimile: (905) 632-3774
Email:
Jenex@sprint.ca

www.jenexcorp.com

 

 

 

   
 
 
HomeContact Us
Management Team
Board of Directors
Advisory Committee
Press Releases
Market Opportunity
Copyright the Jenex Corporation 2001© | Disclaimer